Abstract
We studied four patients with Hodgkin's disease (HD), decreased delayed hypersensitivity skin test responses, and 60% or greater of control mononuclear cell (MNC) blastogenic responses to optimal concentrations of phytohemagglutinin (PHA). All four patients had significantly greater increases in PHA stimulated blastogenic responses when cocultured with 1 μg/ml of indomethacin than did simultaneously studied normal volunteers. These increases improved but did not completely correct the patient MNC PHA hyporesponsiveness noted at suboptimal mitogenetic doses of PHA. Oral indomethacin treatment, averaging 750 mg over 8 days, markedly improved blastogenic responses to suboptimal concentrations of PHA in two patients. Oral treatment did not significantly affect the previously noted increases in patient MNC blastogenic responses on coculture with indomethacin. The results of delayed hypersensitivity skin testing were unchanged by oral drug treatment. This preliminary study supports the hypothesis that oral treatment with indomethacin may improve abnormalities of MNC function in some patients with HD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
